银屑病生物制剂治疗严重感染风险:BADBIR前瞻性队列研究
基于英国BADBIR登记数据,采用倾向评分加权Cox模型比较依那西普、阿达木单抗、乌司奴单抗与非生物系统治疗银屑病患者的严重感染风险。共283例发生严重感染,各生物制剂相比非生物系统治疗及甲氨蝶呤单药的严重感染风险均无显著升高。
要点
- 依那西普、阿达木单抗、乌司奴单抗相比非生物系统治疗严重感染风险无显著增加。
- 相比甲氨蝶呤单药,三种生物制剂严重感染风险亦无显著升高。
- 严重感染风险不应作为选择非生物系统治疗与这三种生物制剂的关键区分因素。
核心结论
- 在银屑病患者中,依那西普、阿达木单抗和乌司奴单抗相比非生物系统治疗或甲氨蝶呤单药,未观察到严重感染风险显著增加。
- 严重感染风险不应成为患者和临床医生在非生物系统治疗与依那西普、阿达木单抗、乌司奴单抗之间选择的关键区分因素。
研究设计与样本
- 英国皮肤科医师协会生物干预登记(BADBIR)前瞻性队列研究,采用倾向评分加权Cox比例风险模型。
- 依那西普队列1352人,阿达木单抗队列3271人,乌司奴单抗队列994人,非生物队列3421人。
主要发现
- 共283例患者发生严重感染。
- 每1000人年严重感染发生率(95%CI):非生物14.2(11.5-17.4);依那西普15.3(11.6-20.1);阿达木单抗13.9(11.4-16.6);乌司奴单抗15.1(10.8-21.1)。
关键数值与推荐
- 相比非生物系统治疗:依那西普HR=1.10(95%CI 0.75-1.60);阿达木单抗HR=0.93(95%CI 0.69-1.26);乌司奴单抗HR=0.92(95%CI 0.60-1.41)。
- 相比甲氨蝶呤单药:依那西普HR=1.47(95%CI 0.95-2.28);阿达木单抗HR=1.26(95%CI 0.86-1.84);乌司奴单抗HR=1.22(95%CI 0.75-1.99)。
临床怎么用
- 为银屑病患者选择非生物系统治疗或依那西普、阿达木单抗、乌司奴单抗时,严重感染风险不应作为关键区分依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Serious infection is a concern for patients with psoriasis receiving biologic therapies. We assessed the risk of serious infections for biologics used to treat psoriasis by comparison with a cohort receiving non-biologic systemic therapies in a propensity score-weighted Cox proportional hazards model using data from the British Association of Dermatologists Biologic Interventions Register. Overall, 1,352; 3,271; and 994 participants were included in the etanercept, adalimumab, ustekinumab cohorts, respectively, and 3,421 participants were in the non-biologic cohort. A total of 283 patients had a serious infection; the incidence rates with 95% confidence intervals (CI) per 1,000 person-years were as follows: non-biologic, 14.2 (11.5-17.4); etanercept, 15.3 (11.6-20.1); adalimumab, 13.9 (11.4-16.6); and ustekinumab, 15.1 (10.8-21.1). No significant increases in the risk of serious infection were observed for etanercept (hazard ratio [HR] = 1.10, 95% CI = 0.75-1.60), adalimumab (HR = 0.93, 95% CI = 0.69-1.26), or ustekinumab (HR = 0.92, 95% CI = 0.60-1.41) compared with non-biologic systemic therapies or methotrexate-only (etanercept: HR = 1.47, 95% CI = 0.95-2.28; adalimumab: HR = 1.26, 95% CI = 0.86-1.84; ustekinumab: HR = 1.22, 95% CI = 0.75-1.99). The risk of serious infection should not be a key discriminator for patients and clinicians when choosing between non-biologic systemic therapies, etanercept, adalimumab, and ustekinumab for the treatment of psoriasis.
引用
- Yiu ZZN, Smith CH, Ashcroft DM, et al. Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2017. PMID: 29054603. doi:10.1016/j.jid.2017.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。